ClinicalTrials.gov
public full text
Public Domain
Treatment Shortening of MDR-TB Using Existing and New Drugs
The purpose of this study is to compare the efficacy of a 'new treatment regimen including delamanid, linezolid, levofloxacin, and pyrazinamide for nine or twelve months (investigational arm)' and 'the standard treatment regimen including injectables for 20 to 24 months (control arm)' for treating fluoroquinolone-sensitive multidrug-resistant tuberculosis.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Shortening Treatment by Advancing Novel Drugs#1153608
- TBTC Study 27: Moxifloxacin vs Ethambutol for TB Treatment#855887
- Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis#1095481
- Expand New Drugs for TB [endTB]#857188
- Effectiveness of a Simplified Short Regimen for Multidrug Resistant Tuberculosis in Uzbekistan#875528
Record · ID 834637
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive